As the South Korean government launches the National Bio-Innovation Committee and accelerates efforts to build a "K-Bio Belt" linking Songdo, Osong, Andong and other hubs, a state-run research institute is urging the country to adopt the operating principles of Boston — the world's top biotech cluster — to organically connect its fragmented domestic ecosystem.
The Bio-Health Policy Research Center at the Korea Health Industry Development Institute has published a report titled "Research on Startup and Cluster Models Through Analysis of the Boston Biotech Ecosystem," offering a deep analysis of the success factors behind the world's leading biotech cluster and charting a path forward for South Korea's industry. The study draws on the firsthand observations of Park Soon-man, a senior researcher at the center who spent the past five years stationed in Boston as head of the institute's US office, directly engaging with the local biotech ecosystem.
According to the report, Boston's ecosystem — which employs 117,108 people in biopharma, generates $42 billion in biopharma-related GDP and hosts 63.2 million square feet of laboratory space, the largest in the United States — owes its success to five core principles: density, public risk-sharing, the transformation of hospitals into R&D platforms, talent circulation and policy continuity. Centered on Kendall Square, universities, hospitals, companies and venture capital firms are packed within walking distance of one another, making spontaneous collaboration routine. Massachusetts General Hospital alone receives $655 million in National Institutes of Health funding, serving as a powerful R&D engine.
South Korea, by contrast, has built 20 biotech clusters nationwide since Chuncheon became the first in 1999, with subsequent hubs including Songdo (manufacturing), Osong (R&D and administration) and Andong (vaccine). The total volume of public funding and infrastructure assets is far from small, the report notes, but the fundamental gap lies not in the elements themselves but in the absence of connectivity — a fragmentation driven by ministerial silos and regional divisions. The report described the National Bio-Innovation Committee, chaired by the prime minister, and its push to build a K-Bio Belt by 2030 — integrating an information platform and linking regional hubs in a radial network — as an important turning point in overcoming these limitations.
To ensure the K-Bio Belt takes root successfully, the report called for institutionalizing a "growth ladder" that allows resources, funding and talent to flow without obstruction, going beyond mere hardware supply. Specifically, it recommended consolidating South Korea's abundant public funding under a unified brand — a "K-Bio SBIR" modeled on the US Small Business Innovation Research program — to create a single access point, and building an "automatic linkage trigger" system that seamlessly connects cluster move-in, R&D funding and clinical-stage progression, eliminating administrative gaps.
The report also called for easing restrictions on research-profit reinvestment at research-focused hospitals and launching a pilot regulatory sandbox that allows physician-scientists to start companies and hold concurrent positions. It added that South Korea should combine the government's "3S1V" regulatory rationalization roadmap with the national integrated bio-big data asset — a 100,000-person database set to open in the fourth quarter of 2026 — to position the country as a "Gateway to Asia" for biotech innovation.
"The key to a Korean-style transformation is not uncritically transplanting the Boston model, but reinterpreting its principles — density, talent circulation and the rest — to fit Korean conditions," Park said. "When we bind our world-leading contract development and manufacturing organization capabilities and our single national health insurance data asset together under an integrated governance structure, we will have a globally competitive innovation hub unlike any other."
silverpaper@heraldcorp.com
